China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that its Category 1 product, GST-HG171/ritonavir, an oral COVID-19 therapy, has been approved for marketing in Macau. This approval expands the availability of the treatment to patients in the region.
Previous NMPA Approval
The product previously received conditional approval from the National Medical Products Administration (NMPA) in November 2023 for the treatment of adult patients with mild to moderate COVID-19. This approval was a significant milestone in the development and deployment of the therapy, highlighting its potential to address the ongoing pandemic.
Significance of the Macau Approval
The approval in Macau marks another important step for Fujian Cosunter Pharmaceutical in making its COVID-19 therapy accessible to a broader patient population. This development underscores the company’s commitment to providing effective treatment options for COVID-19, particularly in regions where the need for such therapies remains high.-Fineline Info & Tech
